Sandra Horning

Clinical Focus

• Cancer > Lymphoma
• Burkitt's Lymphoma
• Burkitt's Lymphoma - Hematology
• Burkitt's Lymphoma - Medical Oncology
• Hodgkin's Disease

Administrative Appointments

• President, ASCO (2005 - 2006)
• President-Elect, ASCO (2004 - 2005)

Honors and Awards

• Alwin C. Rambar-James B. D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2000)

Professional Education

• Board Certification: Oncology, American Board of Internal Medicine (1981)
• Fellowship: Stanford University School of Medicine, CA (1980)
• Board Certification: Internal Medicine, American Board of Internal Medicine (1978)
• Residency: University of Rochester Medical Center, NY (1978)
• Internship: University of Rochester Medical Center, NY (1976)

Postdoctoral Advisees

ChunFang Zhu

Research Interests

The objectives of the clinical research program are:
1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkin’s disease (HD) and the non-Hodgkin’s lymphomas (NHL).

The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.

Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials. Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations

Publications

• Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, Kim Y, Sundram U, Tan D, Horning SJ, Hoppe RT, Natkunam Y, Arber DA "Am J Surg Pathol" 2009 ; 4 (33) : 591-8
• Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG "Biol Blood Marrow Transplant" 2008 ; 7 (14) : 741-7
• Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ "J Clin Oncol" 2007 ; 25 (25) : 3902-7
• Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Advani R, Horwitz S, Zelenetz A, Horning SJ "Leuk Lymphoma" 2007 ; 3 (48) : 521-5
• Non-Hodgkin lymphoma of the breast. Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S "Cancer" 2007 ; 1 (110) : 25-30